S&P 500   3,341.53 (-0.23%)
DOW   27,345.30 (-0.15%)
QQQ   270.90 (-1.36%)
AAPL   445.23 (-2.28%)
MSFT   211.86 (-2.08%)
FB   271.55 (+2.36%)
GOOGL   1,498.81 (-0.41%)
AMZN   3,167.25 (-1.79%)
NVDA   445.68 (-1.71%)
CGC   16.78 (-4.22%)
BABA   249.96 (-5.92%)
TSLA   1,443.66 (-3.08%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.53 (-3.67%)
T   29.98 (+0.47%)
F   6.83 (-1.44%)
ACB   10.09 (-2.13%)
GILD   69.10 (+0.42%)
NFLX   489.66 (-3.81%)
DIS   130.31 (-0.39%)
BAC   25.87 (+1.57%)
BA   169.90 (-1.34%)
S&P 500   3,341.53 (-0.23%)
DOW   27,345.30 (-0.15%)
QQQ   270.90 (-1.36%)
AAPL   445.23 (-2.28%)
MSFT   211.86 (-2.08%)
FB   271.55 (+2.36%)
GOOGL   1,498.81 (-0.41%)
AMZN   3,167.25 (-1.79%)
NVDA   445.68 (-1.71%)
CGC   16.78 (-4.22%)
BABA   249.96 (-5.92%)
TSLA   1,443.66 (-3.08%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.53 (-3.67%)
T   29.98 (+0.47%)
F   6.83 (-1.44%)
ACB   10.09 (-2.13%)
GILD   69.10 (+0.42%)
NFLX   489.66 (-3.81%)
DIS   130.31 (-0.39%)
BAC   25.87 (+1.57%)
BA   169.90 (-1.34%)
S&P 500   3,341.53 (-0.23%)
DOW   27,345.30 (-0.15%)
QQQ   270.90 (-1.36%)
AAPL   445.23 (-2.28%)
MSFT   211.86 (-2.08%)
FB   271.55 (+2.36%)
GOOGL   1,498.81 (-0.41%)
AMZN   3,167.25 (-1.79%)
NVDA   445.68 (-1.71%)
CGC   16.78 (-4.22%)
BABA   249.96 (-5.92%)
TSLA   1,443.66 (-3.08%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.53 (-3.67%)
T   29.98 (+0.47%)
F   6.83 (-1.44%)
ACB   10.09 (-2.13%)
GILD   69.10 (+0.42%)
NFLX   489.66 (-3.81%)
DIS   130.31 (-0.39%)
BAC   25.87 (+1.57%)
BA   169.90 (-1.34%)
S&P 500   3,341.53 (-0.23%)
DOW   27,345.30 (-0.15%)
QQQ   270.90 (-1.36%)
AAPL   445.23 (-2.28%)
MSFT   211.86 (-2.08%)
FB   271.55 (+2.36%)
GOOGL   1,498.81 (-0.41%)
AMZN   3,167.25 (-1.79%)
NVDA   445.68 (-1.71%)
CGC   16.78 (-4.22%)
BABA   249.96 (-5.92%)
TSLA   1,443.66 (-3.08%)
MU   48.24 (-0.94%)
GE   6.42 (+1.42%)
AMD   83.53 (-3.67%)
T   29.98 (+0.47%)
F   6.83 (-1.44%)
ACB   10.09 (-2.13%)
GILD   69.10 (+0.42%)
NFLX   489.66 (-3.81%)
DIS   130.31 (-0.39%)
BAC   25.87 (+1.57%)
BA   169.90 (-1.34%)
Log in

NASDAQ:AMEDAmedisys Stock Price, Forecast & News

$236.97
+1.58 (+0.67 %)
(As of 08/7/2020 01:38 PM ET)
Add
Compare
Today's Range
$235.66
Now: $236.97
$238.19
50-Day Range
$179.88
MA: $209.41
$234.39
52-Week Range
$121.00
Now: $236.97
$237.28
Volume2,047 shs
Average Volume210,390 shs
Market Capitalization$7.69 billion
P/E Ratio61.39
Dividend YieldN/A
Beta0.98
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More
Amedisys logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.96 billion
Cash Flow$6.31 per share
Book Value$22.25 per share

Profitability

Net Income$126.83 million

Miscellaneous

Employees21,300
Market Cap$7.69 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$236.97
+1.58 (+0.67 %)
(As of 08/7/2020 01:38 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amedisys (NASDAQ:AMED) Frequently Asked Questions

How has Amedisys' stock been impacted by COVID-19 (Coronavirus)?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMED shares have increased by 39.0% and is now trading at $236.97.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Amedisys?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amedisys
.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amedisys
.

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings data on Tuesday, July, 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.81 by $0.53. The health services provider had revenue of $485.06 million for the quarter, compared to analyst estimates of $468.38 million. Amedisys had a return on equity of 22.41% and a net margin of 6.50%. Amedisys's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $1.21 earnings per share.
View Amedisys' earnings history
.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of $4.84-5.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.54. The company issued revenue guidance of $2.04-2.07 billion, compared to the consensus revenue estimate of $2.03 billion.

What price target have analysts set for AMED?

13 Wall Street analysts have issued 1-year price objectives for Amedisys' shares. Their forecasts range from $160.00 to $270.00. On average, they expect Amedisys' stock price to reach $224.38 in the next twelve months. This suggests that the stock has a possible downside of 5.3%.
View analysts' price targets for Amedisys
.

Has Amedisys been receiving favorable news coverage?

Media stories about AMED stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a news impact score of 2.1 on InfoTrie's scale. They also gave news headlines about the health services provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Amedisys
.

Are investors shorting Amedisys?

Amedisys saw a drop in short interest in July. As of July 31st, there was short interest totaling 926,200 shares, a drop of 24.1% from the July 15th total of 1,220,000 shares. Based on an average daily volume of 382,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 2.9% of the shares of the company are sold short.
View Amedisys' Current Options Chain
.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
  • Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 52)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.08%), Principal Financial Group Inc. (0.38%), Great Lakes Advisors LLC (0.28%), Retirement Systems of Alabama (0.27%), Russell Investments Group Ltd. (0.23%) and Swiss National Bank (0.22%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys
.

Which institutional investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Russell Investments Group Ltd., Columbus Circle Investors, Calamos Advisors LLC, Great Lakes Advisors LLC, SG Americas Securities LLC, First Trust Advisors LP, and Hancock Whitney Corp. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys
.

Which institutional investors are buying Amedisys stock?

AMED stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Principal Financial Group Inc., New York State Common Retirement Fund, Riverbridge Partners LLC, Swiss National Bank, Essex Investment Management Co. LLC, Empowered Funds LLC, and Polianta Ltd. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $236.97.

How big of a company is Amedisys?

Amedisys has a market capitalization of $7.69 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.